Helius Medical Technologies Reports PoNS Therapy Breakthroughs
Helius Medical Technologies, Inc. (NASDAQ: HSDT), a pioneer in neurotechnology, has unveiled significant findings from the PoNS Therapeutic Experience Program, known as PoNSTEP. This study has revealed the Portable Neuromodulation Stimulator (PoNS) therapy's capacity to enhance gait in individuals suffering from Multiple Sclerosis (MS). With a market presence valued at $3.84 million, Helius is keen on addressing gait deficits experienced by MS patients, showcasing a commitment to advancing neurological health.
The PoNSTEP Study: Long-Term Efficacy Ignited
The PoNSTEP study encompassed 43 participants diagnosed with mild to moderate gait impairments due to MS. The results demonstrated an impressive average improvement of 5.00 on the Dynamic Gait Index (DGI) by the 14th week, supported by statistically valid findings. This improvement showcases PoNS therapy's promise in instigating sustainable progress for patients who struggle with mobility due to neurological disorders.
Adherence to Therapy: A Key Factor
The research underlined that commitment to the therapy regimen is critical for success. During the second phase of the study, an admirable average adherence rate of 71% was noted, leading to remarkable improvements in scores. Participants maintaining higher adherence of 85% or above experienced a mean improvement of 3.7 points in DGI, compared with just 2.0 points for those less compliant. This strong correlation highlights the necessity of consistency in treatment for optimal outcomes.
Long-Lasting Results Indicate Therapeutic Promise
When the participants were re-evaluated six months later, only one out of 28 showed a decline of 30% or more in their DGI scores. This finding strongly suggests that the therapeutic benefits of PoNS therapy are not just temporary but can provide enduring improvements in gait functionality. This research illuminates the role of neuroplasticity in maintaining these enhancements over time, reflecting a positive shift in how MS can be managed.
Insights from Leadership on PoNS Therapy
Dr. Antonella Favit-Van Pelt, Chief Medical Officer of Helius, expressed that the outcomes of the PoNSTEP study represent a pivotal step in understanding how neuromodulation can play a role in rehabilitating gait function. Meanwhile, Helius President and CEO, Dane Andreeff, highlighted his satisfaction with the evident effectiveness of PoNS therapy and reiterated the necessity of treatment compliance for achieving the best results.
Current Accessibility and Future Directions
Currently, PoNS therapy is prescribed in the United States for patients aged 22 and older dealing with gait deficits due to MS. It has also gained acceptance in Canada and Australia for other medical indications. The promising results from the ongoing studies are set to be presented at forthcoming scientific conferences, further advocating for the potential of PoNS therapy to improve the quality of life for individuals with neurological issues.
Market Reactions and Stock Performance
In light of these developments, investor sentiment towards Helius Medical Technologies has been notably favorable. The stock has seen significant returns, with a remarkable increase exceeding 21% in the past week and an impressive 53% rise year-to-date. Such market movements reflect growing confidence in Helius's research advancements and product efficacy.
Ongoing Innovations and Developments
Additionally, Helius Medical Technologies is making strides in its stroke registrational program, having surpassed initial enrollment expectations, a sign of progress in showcasing the effectiveness of PoNS. The company has also secured final Medicare payment rates from the Centers for Medicare and Medicaid Services (CMS) for the PoNS device. This achievement marks a notable milestone, even amidst debates concerning pricing determinations.
Future Prospects for Helius
Looking ahead, preliminary results from the PoNSTEP study signify significant enhancements in DGI scores among MS patients utilizing PoNS therapy. Helius is gearing up for submission to the FDA for stroke treatment authorization and is also investigating the application of PoNS for traumatic brain injury patients. Despite facing a notable revenue dip of 36.62% over the past year, Helius maintains a robust financial outlook, securing stability through a successful public offering.
Frequently Asked Questions
What is PoNS therapy?
PoNS therapy is a non-invasive treatment using a Portable Neuromodulation Stimulator to aid in improving gait deficits, particularly in MS patients.
How effective is PoNS therapy based on recent studies?
The recent PoNSTEP study indicated a significant improvement in gait, with a mean increase of 5.00 in DGI scores after 14 weeks of treatment.
What role does treatment adherence play in PoNS therapy?
Adherence to the therapy regimen is crucial for effectiveness; higher compliance rates correlate with greater improvements in gait scores.
What are the future plans for Helius Medical Technologies?
Helius is focused on expanding the use of PoNS therapy for additional applications, including stroke and traumatic brain injury.
Has Helius seen any recent market success?
Yes, Helius has experienced significant stock performance, with a 21% increase in a week and a 53% increase year-to-date, reflecting positive market sentiment.
